LAG3 and head and neck squamous cell carcinoma: CA224-020 is a phase I/IIa dose escalation and expansion study, exploring BMS-986016 (an anti-LAG-3 antibody) alone and in combination with Nivolumab in advanced solid tumors, including a HNSCC cohort (NCT01968109).